In last trading session, Checkpoint Therapeutics Inc (NASDAQ:CKPT) saw 0.61 million shares changing hands with its beta currently measuring 1.43. Company’s recent per share price level of $3.13 trading at -$0.05 or -1.57% at ring of the bell on the day assigns it a market valuation of $152.85M. That closing price of CKPT’s stock is at a discount of -43.77% from its 52-week high price of $4.50 and is indicating a premium of 55.91% from its 52-week low price of $1.38.

For Checkpoint Therapeutics Inc (CKPT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.

Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information

Upright in the red during last session for losing -1.57%, in the last five days CKPT remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $3.13 price level, adding 8.48% to its value on the day. Checkpoint Therapeutics Inc’s shares saw a change of -2.19% in year-to-date performance and have moved -9.54% in past 5-day. Checkpoint Therapeutics Inc (NASDAQ:CKPT) showed a performance of 13.00% in past 30-days.

Checkpoint Therapeutics Inc (CKPT) estimates and forecasts

This year revenue growth is estimated to fall -86.73% from the last financial year’s standing.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 26.32% during past 5 years.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.09 shares of worth $3.42 million or 2.27% of the total outstanding shares. The later fund manager was in possession of 265.74 shares on Sep 30, 2024 , making its stake of worth around $0.83 million in the company or a holder of 0.55% of company’s stock.